ライフサイエンスコーパス: AAV vector

1 CI-MPR in muscle, was administered with the AAV vector.

2 ansgenes separately, or a single bicistronic AAV vector.

3 ne therapy clinical trials using recombinant AAV vectors.

4 decreased avidity favors systemic spread of AAV vectors.

5 aB in HeLa cells transduced with recombinant AAV vectors.

6 tocol for gene targeting in human cells with AAV vectors.

7 argeted integration of these double-stranded AAV vectors.

8 ignificant hurdle in clinical application of AAV vectors.

9 ization of cell clones containing integrated AAV vectors.

10 s have been developed to better characterize AAV vectors.

11 pecific memory CD8(+) T cells reactivated by AAV vectors.

12 and raise concerns over the clinical use of AAV vectors.

13 ld be co-delivered to TG neurons by separate AAV vectors.

14 a substantial improvement over conventional AAV vectors.

15 relative inaccessibility of BCs to standard AAV vectors.

16 and multiple gRNA expression cassettes with AAV vectors.

17 t for single-stranded and self-complementary AAV vectors.

18 hrough the use of an adeno-associated viral (AAV) vector.

19 igen delivered by an adeno-associated virus (AAV) vector.

20 a single functional adeno-associated virus (AAV) vector.

21 were delivered by an adeno-associated virus (AAV) vector.

22 livery, such as with adeno-associated viral (AAV) vectors.

23 r vectorization into adeno-associated virus (AAV) vectors.

24 replacement genes in adenoassociated virus (AAV) vectors.

25 uced higher transduction than their parental AAV vectors (2- to 9-fold over AAV2), with the highest o

26 th a human SMN-expressing self-complementary AAV vector - a vector that leads to earlier onset of gen

27 ravenous dose of the adeno-associated virus (AAV) vector, AAV-BR1-CAG-NEMO, delivering the Nemo gene

28 fficiency of a novel adeno-associated virus (AAV) vector, AAV2/9, across murine nasal and lung airway

29 Although subretinal (SR) AAV vector administration can transfect retinal cells ef

30 ngly, the antibody response was prevented by AAV vector administration during the 12 wk of ERT, and t

31 in the liver was found after single-stranded AAV vector administration, regardless of the capsid sequ

32 overexpressed via an adeno-associated virus (AAV) vector after the onset of spontaneous recurrent sei

33 ficiency of multiple adeno-associated virus (AAV) vectors after a single injection via intraperitonea

34 guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene

35 to identify photoreceptors transduced by the AAV vector and to localize cone arrestin within cone cel

36 lt mouse brains via stereotaxic injection of AAV vectors and found that it also preferentially accumu

37 hould be considered for design of both safer AAV vectors and gene therapy studies.

38 ish a profile of insertional mutagenesis for AAV vectors and provide unique insight into the chromoso

39 outcome of liver-directed gene therapy using AAV vectors and showed in a proof-of-principle study how

40 ging, new approaches to engineer and improve AAV vectors and their genetic cargo are increasingly hel

41 s were packaged into adeno-associated virus (AAV) vectors and injected into the ventricles of postnat

42 ing of the determinants of immunogenicity of AAV vectors, and of potential associated toxicities, is

43 dministration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S ta

44 LG gene delivery by AAV vectors appears to be both safe and well tolerated.

45 The present work revealed that AAV vectors are able to delivery DNA to the LGs of mice.

46 aging capacity of the vector, trans-splicing AAV vectors are able to package twice the size of the ve

47 Because AAV vectors are administered directly to the patient, th

48 Because AAV vectors are already used for liver-directed human ge

49 Furthermore, we show that single-stranded AAV vectors are better substrates for site-specific inte

50 AAV vectors are nonpathogenic and elicit minimal inflamm

51 Adeno-associated virus (AAV) vectors are attractive for gene delivery-based ther

52 Adeno-associated virus (AAV) vectors are being considered for in vivo applicatio

53 Adeno-associated virus (AAV) vectors are currently being evaluated for the treat

54 Adeno-associated virus (AAV) vectors are currently the leading candidates for vi

55 Adeno-associated virus (AAV) vectors are effective gene delivery vehicles mediat

56 Adeno-associated virus (AAV) vectors are ideal for performing gene repair due to

57 nsduction potential, adeno-associated virus (AAV) vectors are leading candidates for gene therapy in

58 s and opens novel perspectives on the use of AAV vectors as vaccines against emergent diseases.

59 multiple pseudotyped adeno-associated virus (AAV) vectors as a means for achieving systemic distribut

60 from a set of other adeno-associated virus (AAV) vectors as a potent vector for the cochlear cell ta

61 imitations for using adeno-associated virus (AAV) vectors as gene transfer agents to LG.

62 ce by intraperitoneal injection of the PQBP1-AAV vector at E10 successfully rescued microcephaly with

63 Recent reports suggest that AAV vectors based on serotypes 1, 5, and 7 transduce mur

64 adjuvant; in contrast, administration of the AAV vector before the GAA challenge prevented the antibo

65 These results demonstrate that a single AAV vector can complement the CF defect in differentiate

66 Polyploid AAV vectors can be generated from any AAV serotype, whet

67 However, some AAV vectors can be transported along neuronal pathways a

68 a mechanism for integration and suggest that AAV vectors can integrate at existing chromosome breaks

69 been shown that the adeno-associated virus (AAV) vector can deliver the VEGF gene efficiently into t

70 Adeno-associated virus (AAV) vectors can stably express HIV-1 broadly neutralizi

71 ators to dissect the immune responses to the AAV vector capsid and to the transgene product, and to d

72 orchid donor testes were exposed in vitro to AAV vectors carrying a GFP transgene and transplanted to

73 To overcome this obstacle, we constructed AAV vectors carrying the channelrhodopsin-2 (ChR2) gene

74 a self-complementary adeno-associated viral (AAV) vector carrying human RP2-coding sequence and demon

75 and in the brain, an adeno-associated virus (AAV) vector carrying the AIP cDNA was constructed.

76 eletion of mTOR with adeno-associated viral (AAV) vector carrying the Cre recombinase in the hippocam

77 systemic delivery of adeno-associated virus (AAV) vectors carrying human delta-sarcoglycan (delta-SG)

78 ere amplified from human DNA, cloned into an AAV vector cassette upstream of the green fluorescent pr

79 Thus, we did not find evidence that AAV vectors cause insertional activation of oncogenes an

80 tor system to isolate and analyze 977 unique AAV vector-chromosome integration junctions from normal

81 ed a single-stranded adeno-associated viral (AAV) vector consisting of a bioengineered capsid, liver-

82 Since most commonly used recombinant AAV vectors contain a single-stranded DNA (ssDNA), which

83 served in these mice after injection with an AAV vector containing a lacZ gene fragment, and precise

84 AAV-DJ is an artificial chimeric AAV vector containing hybrid capsid sequences from three

85 inner retina after intravitreal injection of AAV vectors containing five distinct promoters.

86 e results highlight the potential utility of AAV vectors containing serotype 5 capsid to deliver and

87 A either in a single vector or in 2 separate AAV vectors containing the heavy- and light-chain cDNAs.

88 gene therapy with an adeno-associated virus (AAV) vector containing a liver-specific promoter elevate

89 passionate use of an adeno-associated virus (AAV) vector containing the human AADC gene (AAV2-hAADC)

90 ion of a recombinant adeno-associated virus (AAV) vector containing the RPE65 gene (AAV2-hRPE65v2) in

91 Adeno-associated virus (AAV) vectors containing single-stranded DNA efficiently

92 Here, we used adeno-associated virus (AAV) vectors containing the astrocyte-specific Gfa2 prom

93 s study, we injected adeno-associated virus (AAV) vectors containing the human CLN2 cDNA into the bra

94 IIa (mFVIIa) from an adeno-associated viral (AAV) vector corrected abnormal hemostatic parameters in

95 Thus, CpG-depleted AAV vectors could improve outcome of clinical trials of

96 ery of costimulatory inhibitor transgenes by AAV vectors could prevent and reverse lupus in this muri

97 with stereotaxic injection of 5-HT2CR shRNA AAV vector decreased vocalizations and anxiety- and depr

98 sgenic mice using an adeno-associated virus (AAV) vector, decreased parenchymal Abeta amyloid deposit

99 e inhibitory to the tested human and primate AAV vectors delivered into the circulatory system.

100 strophic mdx(4cv) mice using single and dual AAV vector delivery of a muscle-specific Cas9 cassette t

101 The combination of an AAV vector delivery system and exploitation of the endog

102 By using adeno-associated viral (AAV) vector delivery in vivo, we achieved long-term expr

103 report that systemic adeno-associated virus (AAV) vector delivery of zinc finger nucleases (ZFNs) and

104 sgene cassette using adeno-associated virus (AAV) vector delivery.

105 Thus, the new HSV/AAV vector demonstrated unique advantages in safe and ef

106 Tumors in mice treated with AAV vectors did not have significantly different amounts

107 Infection with AAV vectors did not increase mutation rates in normal hu

108 In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the ti

109 All pseudotyped AAV vectors elicited serum anti-AAV capsid-neutralizing

110 We administered 10(9) particles of an AAV vector encoding human erythropoietin (hEPO) directly

111 Injection of a double-stranded AAV vector encoding IL-2 driven by a mouse insulin promo

112 AAV vectors encoding firefly luciferase were administere

113 As proof of concept, delivery of AAV vectors encoding for hexokinase or vascular endothel

114 adapted an intravascular delivery system of AAV vectors encoding the FIX transgene to skeletal muscl

115 inal injection of an adeno-associated virus (AAV) vector encoding ARES, luciferase expression can be

116 ly manipulated by an adeno-associated virus (AAV) vector encoding BMP4 delivered by a clinically appl

117 We used an adeno-associated viral (AAV) vector encoding green fluorescent protein under an

118 Introduction of an adeno-associated viral (AAV) vector encoding IL-4 into the hippocampus resulted

119 gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with th

120 ) with CRE-dependent adeno-associated viral (AAV) vector encoding the engineered Gi/o-coupled human m

121 administration of an adeno-associated virus (AAV) vector encoding the human DOK7 gene resulted in an

122 Recombinant adeno-associated virus (AAV) vectors encoding the growth factors were injected t

123 long-term effect of adeno-associated viral (AAV) vector-encoding vascular endothelial growth factor

124 In six pigs, adeno-associated viral (AAV) vector-encoding VEGF (AAV-VEGF) gene was injected a

125 we demonstrate that adeno-associated viral (AAV) vectors, especially serotypes 8 and 9, mediated eff

126 rcinoma (HCC) after neonatal injection of an AAV vector expressing b-glucuronidase.

127 eral infusions of a retrogradely transported AAV vector expressing Cre recombinase (Retro-Cre-GFP) in

128 Four weeks after disease induction, AAV vector expressing the vIL-10 gene under control of a

129 AAV vectors expressing CTLA-4Ig or CD40Ig were injected

130 arate cohort was injected with CRE-dependent AAV vectors expressing diphtheria toxin (DTA) to selecti

131 f-complementary adenovirus-associated virus (AAV) vector expressing a codon-optimized human factor IX

132 y to the VMH with an adeno-associated viral (AAV) vector expressing a short hairpin RNA for AMPKalpha

133 6 was depleted using adeno-associated viral (AAV) vector expressing CD36 short hairpin RNA (shRNA) in

134 s of a Cre-dependent adeno-associated viral (AAV) vector expressing enhanced halorhodopsin 3.0 fused

135 enous infusion of an adeno-associated viral (AAV) vector expressing factor IX.

136 iated by AAV-GPE, an adeno-associated virus (AAV) vector expressing G6Pase-alpha directed by the huma

137 In this study, an adeno-associated virus (AAV) vector expressing human SMN (AAV8-hSMN) was injecte

138 to hepatocytes using adeno-associated virus (AAV) vectors expressing hepatic transcription factors.

139 jection, recombinant adeno-associated virus (AAV) vectors expressing short hairpin RNAs profoundly im

140 athway in rats using adeno-associated virus (AAV) vectors expressing the astrocyte-specific promoter

141 sduction patterns of adeno-associated virus (AAV) vectors following delivery to the developing retina

142 he potential of CREATE to produce customized AAV vectors for biomedical applications.

143 and improving the safety profile of existing AAV vectors for gene therapy.

144 proaches to the molecular evolution of novel AAV vectors for human gene therapy applications.

145 nd their application to characterize current AAV vectors for preclinical and clinical use.

146 ut also provide a general approach to tailor AAV vectors for systemic or hepatic gene transfer by ree

147 eering and payload design aimed at tailoring AAV vectors for transduction and treatment of cancer cel

148 n gene therapy using adeno-associated viral (AAV) vector for hemophilia B (HB) showed that the risk o

149 ommercially available adenoassociated virus (AAV) vector for siRNA delivery into mammalian cells.

150 we review the use of adeno-associated virus (AAV) vectors for delivery of HIV bNAbs and antibody-like

151 We investigated adeno-associated virus (AAV) vectors for gene delivery to the TG after intraderm

152 and effective use of adeno-associated viral (AAV) vectors for gene therapy.

153 f seven serotypes of adeno-associated virus (AAV) vectors for genetic manipulation of primary culture

154 ed gene therapy with adeno-associated viral (AAV) vectors for hemophilia.

155 Use of adeno-associated viral (AAV) vectors for liver-directed gene therapy has shown c

156 The adeno-associated virus (AAV) vector gene delivery system has shown promise in se

157 With this in mind, adeno-associated virus (AAV) vector gene delivery was used to localize IL-2 expr

158 g second-strand synthesis in single-stranded AAV vector genomes and to facilitate robust transgene ex

159 The use of hybrid ITR AAV vector genomes provides new strategies to manipulate

160 efficiency, significantly higher numbers of AAV vector genomes were successfully delivered to the nu

161 Gene targeting with adeno-associated virus (AAV) vectors has been demonstrated in multiple human cel

162 (less than 5 kb) of adeno-associated virus (AAV) vectors has been effectively doubled with the devel

163 Gene transfer using adeno-associated virus (AAV) vectors has great potential for treating human dise

164 AAV vectors have achieved positive results in a number o

165 For cancer applications, AAV vectors have been harnessed for delivery of an exten

166 me receptor.IMPORTANCE Over the past decade, AAV vectors have emerged as leading gene delivery tools

167 Adeno-associated virus (AAV) vectors have been most successful; to target the ou

168 Adeno-associated viral (AAV) vectors have been successfully used for therapeutic

169 Although adeno-associated viral (AAV) vectors have been successfully used in hepatic gene

170 in gene therapy with adeno-associated virus (AAV) vectors have been the object of almost two decades

171 Adeno-associated virus (AAV) vectors have been used successfully in clinical tri

172 Adeno-associated virus (AAV) vectors have been widely adopted for use in gene th

173 Adeno-associated virus (AAV) vectors have made great progress in their use for g

174 Adeno-associated virus (AAV) vectors have the potential to promote long-term gen

175 therapies utilizing adeno-associated viral (AAV) vectors hold great promise for treating Duchenne mu

176 However, as with other AAV vectors, host anti-capsid immune responses are a det

177 Delivery of a single AAV vector in the lung generated loss-of-function mutati

178 t been completed, despite the ongoing use of AAV vectors in clinical trials.

179 can be avoided by enhancing the efficacy of AAV vectors in hepatocytes.

180 greatly improved transduction efficiency of AAV vectors in human and mouse hepatocytes independent o

181 gnificant implications in the optimal use of AAV vectors in human gene therapy.

182 plications in the optimal use of recombinant AAV vectors in human gene therapy.

183 cations for the potential use of these novel AAV vectors in human gene therapy.

184 ection site following subretinally delivered AAV vectors in normal dogs.

185 in trans, we designed a system for producing AAV vectors in which expression of one capsid protein is

186 A expression with an adeno-associated virus (AAV) vector in GAA-knockout (KO) mice.

187 n be transduced with adeno-associated virus (AAV) vectors in vivo, in a manner that would be useful f

188 nger genetic elements to be packaged into an AAV vector including tissue-specific promoters, multiple

189 both single-stranded and self-complementary AAV vectors indicate that the genomes are largely packag

190 ssion of HMGB1 using adeno-associated virus (AAV) vectors induced inflammation in the hearts of both

191 smid transfection and 4- to 6-fold lower for AAV vector infection), but they still represented a sign

192 novel high-throughput method for identifying AAV vector integration sites was developed and used to c

193 ensive evaluation of adeno-associated virus (AAV) vector integration sites has not been completed, de

194 Remarkably, loading AAV vectors into pSi microparticles increases gene deliv

195 We found that a direct microinjection of AAV vectors into the vagal nodose ganglia in vivo leads

196 This new HSV/AAV vector is designed in a way that little or no Rep wo

197 nactive, efficient transgene expression from AAV vectors is dependent upon viral second-strand DNA sy

198 The eGFP encoded by AAV vectors is robustly transported to both the central

199 luation of nNOS binding mini-dystrophin dual AAV vectors is warranted in dystrophic dogs and eventual

200 ion with recombinant adeno-associated virus (AAV) vectors is limited by the need to convert its singl

201 y the status of ss AAV genomes, we generated AAV vectors labeled with bromodeoxyuridine (BrdU), a nuc

202 Delivery of the AAV vector led to RPGRIP expression and restoration of n

203 et of gene expression compared with standard AAV vectors - led to improved efficacy of gene therapy,

204 ted in humans and additional modification to AAV vectors may be required for further study in order t

205 humoral immunity to adeno-associated virus (AAV) vectors may limit their clinical utility in gene de

206 These data support AAV vector-mediated expression of a comparable truncated

207 Thus, AAV vector-mediated gene therapy induced a tolerance to

208 ance between tolerance and immunogenicity in AAV vector-mediated gene transfer are not fully understo

209 VP16, an NF-kappaB activator, augmented AAV vector-mediated transgene expression up to 25-fold.

210 ional silencing upon adeno-associated viral (AAV) vector-mediated expression in photoreceptors.

211 ibe a novel study of adeno-associated virus (AAV) vector-mediated gene therapy that induced immune to

212 nt tissue target for adeno-associated viral (AAV) vector-mediated gene transfer of the factor IX (FIX

213 f IFN-beta following adeno-associated virus (AAV) vector-mediated gene transfer resulted in significa

214 Adeno-associated virus (AAV) vector-mediated transfer of a normal cDNA can corre

215 An AAV vector, MLCVEGF, with 250 bp of the MLC-2v promoter

216 AAV vectors must reach the nucleus in order to deliver t

217 We demonstrated that AAV vectors of serotypes 1, 7, 8, and 9 trafficked from

218 Therefore, novel nonprimate AAV vectors or compartmentalized delivery may offer more

219 No significant apoptosis related to AAV vectors or IDUA was observed under any conditions in

220 In this study, a very low number of AAV vector particles was administered before initiation

221 Biodistribution analyses suggested AAV vectors persisted only in the trauma-induced corneas

222 This corroborates our current model for AAV vector persistence in the liver and provides useful

223 mice was fully rescued by treatment with the AAV-vectored PHF1 antibody.

224 ibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV

225 The self-complementary AAV vector preparation appears to contain particles with

226 AAV vectors produce stable transgene expression and elic

227 atum, we injected an adeno-associated virus (AAV) vector producing a short hairpin RNA (AAV.sh.p11).

228 th as a raw material (e.g. in lentiviral and AAV vector production) as well as an active ingredient (

229 poxia-regulated, retinal glial cell-specific AAV vector provides a platform for gene therapy within r

230 mbination events required for efficient dual-AAV vector reconstitution of the transgene.

231 Moreover, intracerebral infusion of the AAV vector resulted in robust AIP expression in the hipp

232 jection of 2 x 10(11) vg/kg of the hFVIIcoop AAV vector resulted in therapeutic levels of hFVII expre

233 imilarly, coadministration of rapamycin with AAV vectors resulted in markedly enhanced expression of

234 mic and intravitreal injection of engineered AAV vectors resulted in RdCVF and RdCVFL expression in t

235 iated by recombinant adeno-associated virus (AAV) vectors resulted in significant antiapoptotic activ

236 as well as to a novel, structurally distinct AAV vector, rh32.33, in an in vitro transduction inhibit

237 of this association and the implications for AAV vector safety.

238 positive for the presence of the transferred AAV vector sequence.

239 To evaluate systemic toxicity, we measured AAV vector sequestration in the liver using qPCR, and fo

240 Adeno-associated viral (AAV) vectors (serotype 2) efficiently transduce skeletal

241 arrow reconstitution of mice treated with an AAV vector several weeks earlier.

242 this approach in generating custom-designed AAV vectors should be of significant value to the field

243 F-kappaB inhibitors before transduction with AAV vectors should lead to a dampened immune response, w

244 ons of HBV delivered by a self-complementary AAV vector showed better antiviral effects than single s

245 ophilia B (HB) using adeno-associated viral (AAV) vectors showed that the safety of a given strategy

246 hic factor, using an adeno-associated virus (AAV) vector significantly increased the neuritin level a

247 y, questions have arisen about the safety of AAV vectors, specifically, whether integration of vector

248 Rhesus macaques inoculated with an AAV vector stably expressed 17-77 mug ml(-1) of fully fu

249 c biology of AAV, the history of progress in AAV vector technology, and some of the clinical and rese

250 ith both plasmid and adeno-associated virus (AAV) vector templates.

251 These studies have led to the development of AAV vectors that are capable of high-efficiency transduc

252 in mdx and mdx4cv mice using a pair of dual AAV vectors that expressed a 6 kb nNOS-binding mini-dyst

253 ts may lend insight into the design of novel AAV vectors that have an enhanced nuclear entry capabili

254 h the circular episomal forms of recombinant AAV vectors that have been isolated and characterized fr

255 he development of an adeno-associated viral (AAV) vector that rescues rhodopsin mislocalization, main

256 the effect of HBV on adeno-associated viral (AAV) vectors, the most frequently applied gene transfer

257 ific integration than are self-complementary AAV vectors; the absence of DNAPKcs did not affect the t

258 ly cross the blood-brain barrier, we used an AAV vector to deliver antibody directly to the hippocamp

259 ese studies show that the use of recombinant AAV vector to deliver genes is a promising approach for

260 y is the first to use a recombinant chimeric AAV vector to knockout a gene in porcine fibroblasts for

261 es, including those packaged into serotype 1 AAV vectors to allow use of lower viral doses.

262 This review describes the applications of AAV vectors to cancer models and presents developments i

263 Using AAV vectors to deliver antibodies like PHF1 directly to

264 A related approach uses AAV vectors to edit specific regions of the DMD gene usi

265 The goal was to investigate the ability of AAV vectors to induce long-term, safe delivery of transg

266 velopment can be exploited to redirect novel AAV vectors to specific cell types in the brain.

267 Airway-based delivery of AAV vectors to the pulmonary arteries was feasible, effi

268 ving vector efficacy may improve delivery of AAV vectors to their therapeutic targets.

269 We have used an adeno-associated viral (AAV) vector to deliver the genes encoding an anti-phosph

270 further injected an adeno-associated viral (AAV) vector to express IVS-AAA in the brain of a knock-i

271 ar administration of adeno-associated virus (AAV) vectors to 16 primates.

272 , we created several adeno-associated virus (AAV) vectors to deliver genes that combat oxidation.

273 When using adeno-associated viral (AAV) vectors to express luciferases in the brain, we fou

274 n this study, we use adeno-associated viral (AAV) vectors to increase Perm1 expression in skeletal mu

275 and guide RNAs using adeno-associated viral (AAV) vectors to target single (Mecp2) as well as multipl

276 ach provides design strategies to expand the AAV vector toolkit.

277 potential strategies to redirect recombinant AAV vectors toward more productive trafficking pathways

278 Adeno-associated virus (AAV) vectors transduce cells by multiple pathways, inclu

279 Our data strongly suggest that AAV vector-transduced cells are rarely eliminated by AAV

280 sented here provide the first description of AAV vectors transducing neurons following delivery at th

281 r, AAV receptors contribute significantly to AAV vector transduction efficiency and tropism.

282 ploited to develop new strategies to improve AAV vector transduction efficiency.

283 following a corneal intrastromal injection, AAV vector transduction kinetics, using a chimeric AAV c

284 d function following adeno-associated virus (AAV) vector transduction of MPS1 patient fibroblasts.

285 Recombinant adeno-associated virus 2 (AAV) vectors transduction efficiency varies greatly in d

286 fficiently regulated adeno-associated virus (AAV)-vectored transgene expression in cultured mammalian

287 None of the dogs (n = 14) receiving the AAV vector under transient IS developed inhibitory antib

288 The AAV vector was delivered into the right eyes of RPGRIP(-

289 The AAV vector was tested in vivo by subretinal injections i

290 e-directed expression of canine FIX-R338L by AAV vectors was carried out in HB dogs.

291 MRI-guided technology for administration of AAV vectors we have developed and now employ in current

292 Using an adeno-associated viral (AAV) vector, we expressed the regeneration-promoting cel

293 anial and intrathecal injections of the same AAV vector were combined.

294 AAV vectors were constructed that use a liver-specific p

295 led to the development of novel recombinant AAV vectors which are more efficient in allowing increas

296 WT and Tlr9-deficient mice that received an AAV vector with an immunogenic capsid, AAVrh32.33.

297 ation for rational structural engineering of AAV vectors with improved therapeutic efficacy.

298 ion to date from a parenterally administered AAV vector, with broad implications for the future of mu

299 er-specific expression of human GAA with the AAV vector would induce immune tolerance and enhance the

300 doses of recombinant adeno-associated virus (AAV) vectors would allow for therapeutic levels of trans